Nicotine Ayrton Saunders (Ireland) (Nicotine)

The nicotine in this inhaler binds to neuronal nicotinic acetylcholine receptors, especially the α4β2 subtype, stimulating dopamine release in the brain’s reward pathways. This mimics the effect of tobacco‑derived nicotine, easing withdrawal and decreasing the urge to smoke while allowing a gradual reduction in nicotine exposure.

The appropriate dose is determined by the prescribing healthcare professional based on the individual’s smoking history, level of dependence, and overall health. The product is supplied without a fixed regimen, and patients should follow the prescriber’s instructions for frequency and duration of use.

Safety in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their healthcare provider before using any nicotine replacement product, as nicotine can cross the placenta and enter breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Compared with nicotine patches or gum, the inhalation form delivers nicotine more rapidly to the lungs, providing a sensory experience similar to smoking. This can be advantageous for individuals who miss the hand‑to‑mouth habit. However, patches offer steady plasma levels, and gum allows dose titration, so choice depends on patient preference and clinical considerations.

Store the inhaler at ambient temperature, preferably below 25 °C, in its original packaging. Keep it away from direct sunlight, moisture, and heat sources. Ensure the device is sealed when not in use to maintain product integrity and prevent accidental exposure.

The product is used by inhalation. The user draws the prescribed number of puffs from the inhaler, allowing the nicotine aerosol to reach the lungs. Administration technique and frequency should follow the prescribing clinician’s guidance to achieve optimal symptom control while minimizing the risk of over‑use.

Serious risks include allergic reactions such as rash, swelling, or difficulty breathing, as well as bronchospasm and chest pain, which may indicate cardiovascular strain. If any of these symptoms occur, the user should discontinue the product immediately and seek medical attention.

Individuals with uncontrolled hypertension, recent myocardial infarction, severe arrhythmias, or known hypersensitivity to nicotine should avoid this product. It is also contraindicated for people using other nicotine replacement therapies simultaneously, unless directed by a healthcare professional.